



Emergent BioSolutions to Release First Quarter 2007 Financial Results on May 9, 2007

April 25, 2007

ROCKVILLE, Md.--(BUSINESS WIRE)--April 25, 2007--Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the first quarter 2007 on Wednesday, May 9, 2007, before market open.

As previously stated by company management, the company will not be hosting conference calls related to its quarterly financial results.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

CONTACT: Emergent BioSolutions Inc.

Robert G. Burrows, 301-795-1877

Vice President, Corporate Communications

burrowsr@ebsi.com

SOURCE: Emergent BioSolutions Inc.